AAPL vs LLY: Which Is the Better Buy?
Side-by-side comparison of Apple Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-13.
Apple Inc. · Technology
$294.80
-9.3% upside to fair value
Grade B-
High Quality
VS
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+17.6%).
LLY trades at a lower forward P/E
(33.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AAPL |
LLY |
| Current Price |
$294.80 |
$934.34 |
| Fair Value Estimate |
$267.40 |
$1,098.43 |
| Upside to Fair Value |
-9.3%
|
+17.6%
|
| Market Cap |
$4,329.8B |
$882.8B |
| Forward P/E |
35.4x
|
33.1x
|
| EV / EBITDA |
27.3x
|
27.9x
|
| Price / Sales |
9.6x
|
12.2x
|
| Price / FCF |
33.5x
|
65.0x
|
| Revenue Growth YoY |
+16.6%
|
+55.5%
|
| Gross Margin |
47.9%
|
82.7%
|
| Operating Margin |
32.6%
|
46.3%
|
| Return on Equity |
146.7%
|
101.3%
|
| Dividend Yield |
0.34% |
0% |
| FCF Yield |
2.98%
|
1.54%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Apple Inc. is the world's most valuable consumer technology company, anchored by the iPhone franchise and a roughly $100 billion annual Services business that compounds at a low-to-mid teens rate on an installed base of approximately 2.5 billion active devices. Fiscal Q2 2026 results reported on April 30 showed revenue of $111.2 billion (+16.6% YoY) and EPS of $2.02 (+22.4% YoY), driven by a cont…
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Accumulation Zones
| Metric |
AAPL |
LLY |
| Zone Low |
$200.50 |
$823.82 |
| Zone High |
$227.30 |
$933.67 |
| In Buy Zone? |
No
|
No
|